Bioniz Therapeutics is an emerging biopharmaceutical company leading the discovery and development of first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and cancer.
Originating in research conducted at the National Institutes of Health (NIH), Bioniz is leveraging its expertise in cytokine biology to create a new class of therapeutics that ...
Bioniz Therapeutics is an emerging biopharmaceutical company leading the discovery and development of first-in-class peptide therapeutics that selectively and simultaneously inhibit multiple cytokines to treat immuno-inflammatory diseases and cancer.
Originating in research conducted at the National Institutes of Health (NIH), Bioniz is leveraging its expertise in cytokine biology to create a new class of therapeutics that will tackle the issue of cytokine redundancy. Cytokine redundancy refers to how the immune system uses multiple cytokines sharing overlapping functions to prevent immune system failures from single cytokine malfunctions.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.